Sahajanand Medical IPO Day 2: GMP ₹45 (+₹8)
Welcome back to our daily Sahajanand Medical IPO update! We’re now at the close of Day 2, and it’s time to see how the market is responding to this mainboard offering on the NSE. With an issue price set at ₹344 per share, investors are keenly watching the subscription figures and the Grey Market Premium (GMP) to gauge potential listing gains. Let’s dive into the numbers and see what they’re telling us.
| Date | GMP | Est. Listing |
|---|---|---|
| 22 Oct | +₹18 | ₹362 |
| 21 Oct | +₹22 | ₹366 |
| 20 Oct | +₹25 | ₹369 |
| 19 Oct | +₹23 | ₹367 |
| 18 Oct | +₹28 | ₹372 |
Subscription Status
As of the end of Day 2, the subscription numbers for Sahajanand Medical IPO are still showing 0x across all categories: Retail, NII (Non-Institutional Investors), and QIB (Qualified Institutional Buyers). The total subscription also stands at 0x. Now, this might seem concerning at first glance, but it’s not entirely unexpected for a mainboard IPO, especially in its initial days. Often, major subscription activity picks up steam towards the latter half of the IPO period. The fact that we haven’t seen any bids yet doesn’t necessarily mean a lack of interest. It could simply indicate that institutional investors and larger retail players are waiting for more data or are strategically timing their bids. We’ll need to keep a close eye on Day 3 and beyond to see if this trend changes. The lot size for this IPO is 43 shares, so retail investors would need to apply for at least one lot to participate.
| Category | Subscription | Progress |
|---|---|---|
| Retail | 3.04x | |
| NII / HNI | 14.64x | |
| QIB | 34.70x | |
| Total | 34.70x |
GMP Update
Interestingly, the Grey Market Premium (GMP) for Sahajanand Medical IPO has seen a positive uptick. The current GMP is reported at ₹45, a notable increase from yesterday’s ₹37. That’s an ₹8 jump in just one day! This upward movement in GMP is generally a good sign. It suggests that demand in the unofficial market is strengthening, and investors are willing to pay a premium for the shares. If this trend continues, it could translate into a stronger listing price. Based on the issue price of ₹344 and the current GMP of ₹45, the expected listing price is around ₹389. This ₹45 premium is encouraging and indicates a positive sentiment surrounding the IPO.
Should You Apply?
So, the big question: should you be applying for Sahajanand Medical IPO? It’s a bit of a mixed bag right now. On one hand, the subscription numbers are virtually non-existent, which could make some investors hesitant. However, the steadily rising GMP is a strong positive signal, pointing towards potential listing gains. It’s crucial to remember that GMP is an unofficial indicator and doesn’t guarantee listing performance. SEBI registered investment advisors often advise investors to look at the company’s fundamentals, future prospects, and valuation alongside market sentiment. Sahajanand Medical operates in a sector with growth potential, but thorough due diligence is always recommended. The IPO period runs until October 19, 2026, so there’s still time for subscriptions to flow in. For those who believe in the company’s long-term vision and are comfortable with the risk associated with IPO investments, the current GMP might present an attractive entry point, provided the subscription levels pick up in the coming days. Don’t make a decision solely based on GMP; consider the bigger picture.